Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 18/20 | 1.00 |
| ▸ | AKT1 | P31749 | 3/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19368639 | 0.96 | AKT2 (0.93) | AKT2AKT1CYP2C9CYP2D6RPS6KB1 | |
| SCHEMBL1003864 | 0.89 | AKT2 (1.00) | AKT2AKT1CYP2C9CYP2D6RPS6KB1 | |
| SCHEMBL1003013 | 0.88 | AKT2 (1.00) | AKT2AKT1CYP2C9CYP2D6RPS6KB1 | |
| SCHEMBL13540025 | 0.82 | AKT2 (0.78) | AKT2AKT1CYP2C9CYP2D6RPS6KB1 | |
| SCHEMBL1003586 | 0.82 | AKT2 (1.00) | AKT2AKT1CYP2C9CYP2D6RPS6KB1 | |
| SCHEMBL1003972 | 0.82 | AKT2 (0.76) | AKT2AKT1CYP2C9CYP2D6RPS6KB1 | |
| SCHEMBL1001861 | 0.81 | AKT2 (1.00) | AKT2AKT1CYP2C9CYP2D6RPS6KB1 | |
| SCHEMBL2781525 | 0.81 | AKT2 (1.00) | AKT2AKT1CYP2C9CYP2D6RPS6KB1 | |
| SCHEMBL3993001 | 0.79 | AKT2 (0.71) | AKT2AKT1CYP2C9CYP2D6RPS6KB1 | |
| SCHEMBL1001918 | 0.77 | AKT2 (1.00) | AKT2AKT1CYP2C9CYP2D6RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | claimed |
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3719018-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Ltd (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719018-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Ltd (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3421471-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-2272517-B2 | ORTHO -CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2017-09-20 | — | — | EP | disclosed |
| EP-2272517-B2 | ORTHO -CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2017-09-20 | — | — | EP | disclosed |
| US-9006430-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| CN-101489559-A | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LTD (GB) | 2009-07-22 | — | — | CN | disclosed |
| CN-101484173-A | Pharmaceutical combinations of pk inhibitors and other active agents | ASTEX THERAPEUTICS LTD (GB) | 2009-07-15 | — | — | CN | disclosed |
| EP-2043655-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20090082370-A1 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents | ASTEX THERAPEUTICS LIMITED (GB) | 2009-03-26 | — | — | US | disclosed |
| EP-2037931-A2 | PHARMACEUTICAL COMBINATIONS OF PK INHIBITORS AND OTHER ACTIVE AGENTS | Astex Therapeutics Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007125321-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125321-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125310-A2 | PHARMACEUTICAL COMBINATIONS OF PK INHIBITORS AND OTHER ACTIVE AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK2, CDK1, OXSR1 | AKT2 496/4885AKT1 388/4885CYP2C9 2345/4885 |
| US-20090082370-A1 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents | PKN2, PKN1, PKN3 | AKT2 523/4885AKT1 462/4885CYP2C9 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.